RxDoctor Payments Data

Jana Robison

Psychiatric/Mental Health · Everett, WANPI 1467177469

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.4% of the total across 246 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 23.2% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,630, 3.0 times the $873 reported in 2023. Among psychiatric/mental health clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$5,272in general payments, 2019–2025

Across 246 payments — averaging $21.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
  • Alkermes, Inc.$475
  • AbbVie$456
  • Otsuka America Pharmaceutical, Inc.$418
  • Johnson & Johnson$414
  • Teva Pharmaceuticals USA, Inc.$409
  • plus $2K from 12 others

What the payments were for

  • Food & beverage$5,13497%
  • Education$1393%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,272 in reported general payments places this provider in the 95th percentile of 931 psychiatric/mental health providers in Washington.

See all psychiatric/mental health providers in Washington

Medicare billing

Part B allowed, 2024
$7,114
Medicare patients
17
Services billed
76

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lurasidone Hcl19$3,935
Venlafaxine Hcl ErVenlafaxine Hcl16$1,044
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine13$449
Olanzapine14$436
Quetiapine Fumarate32$360
Bupropion Hcl SrBupropion Hcl11$351
Prazosin Hcl19$324
Lamotrigine15$284
Clonazepam24$215
Trazodone Hcl19$165
Aripiprazole11$141
Lorazepam15$50

Paid to pharmacies, not to this prescriber.

Other psychiatric/mental health in Everett

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →